On April 30, 2025, Quanterix Corporation announced an amended merger agreement with Akoya Biosciences that removes the opportunity for shareholders to vote on the transaction, despite significant opposition as evidenced by vote reports. This decision has drawn sharp criticism from Kent Lake, a major shareholder, who views it as a blatant disregard for shareholder rights and democratic accountability.

On March 3, 2025, Quanterix Corporation highlighted its proposed acquisition of Akoya Biosciences, emphasizing the strategic benefits, expanded market opportunities, and clear long‐term value creation. The company also addressed director nomination challenges from Kent Lake, asserting a commitment to constructive shareholder engagement and robust corporate governance.

Activist shareholder Kent Lake, who owns 6.9% of Quanterix’s stock, has nominated three independent candidates for the board of directors at the 2025 annual meeting. In a public statement, Lake criticized the company's proposed merger with Akoya Biosciences, arguing that it would dilute existing shareholder value, introduce undue risk, and distract from core organic growth opportunities, particularly in research and Alzheimer’s testing.

Kent Lake, which holds 5.9% of Quanterix's common stock, issued an open letter urging shareholders to vote against the proposed merger with Akoya Biosciences. The letter claims that the merger significantly undervalues Quanterix, would deplete substantial cash reserves, and jeopardizes the company’s long-term financial stability, effectively serving as a bailout for Akoya at the expense of existing shareholders.

The Schall Law Firm has launched an investigation into Quanterix Corporation over allegations that the company issued false and/or misleading statements and failed to disclose material information, potentially violating securities laws.

Quanterix Corporation is under investigation by the Rosen Law Firm for allegedly issuing misleading financial statements. An SEC current report on November 12, 2024 indicated that its Audit Committee recommended that previous financial statements should no longer be relied upon, contributing to an 18.3% drop in the stock price and raising serious investor concerns about the company's ethical business practices.

Quanterix Corporation announced partnerships with five major health networks, including AdventHealth, Mass General Brigham, Mayo Clinic, MUSC, and UPMC, to integrate its advanced Simoa technology into Alzheimer’s disease diagnosis. This initiative aims to build global infrastructure for accessible, non-invasive blood biomarker testing, potentially transforming early detection and management of Alzheimer’s.